Safety Considerations for Povorcitinib in HS

Dr. Porter explains that while JAK inhibitors carry boxed warnings for serious risks—such as thromboembolism, malignancies, and major adverse cardiac events—the HS patient population is generally younger than the rheumatoid arthritis cohorts where these risks were first highlighted. However, she notes that HS patients often possess baseline risk factors, as over half of the trial participants were smokers and the average BMI was over 30. Despite these factors, no such major events were reported during the initial 12-week placebo-controlled period, though one thromboembolic event occurred during the extension following a long-haul flight.

The experts also detailed more common, manageable side effects like dose-dependent acne, often referred to as JAKne. These cases remained mild-to-moderate and were easily addressed with standard topical or oral therapies. Other side effects, such as nasopharyngitis and headaches, were consistent with those seen in other immunosuppressive trials and rarely led to treatment discontinuation. Regarding laboratory monitoring, Dr. Porter observed an interesting trend where HS patients’ baseline anemia and elevated white cell counts often normalized as their systemic inflammation was treated by the medication, suggesting that the therapy's JAK1 selectivity helped minimize hematologic abnormalities.

Dr. Lev-Tov compares the management of JAK inhibitors to his long-term experience with cyclosporine, emphasizing that the therapeutic trade-off is often justified in severe cases. He suggests that with proper patient selection, informed consent regarding risks like clotting, and consistent monitoring, the significant quality-of-life benefits for HS patients outweigh the potential for adverse events. The discussion concludes with the sentiment that understanding the drug's mechanism and the patient's underlying risk profile allows clinicians to use these potent tools effectively and safely.

Our next episode further explores HS, highlighting the panelist’s final thoughts and key takeaways on the emerging landscape in HS.